- Home
- FSFG vs MDWD Comparison
FSFG vs MDWD Comparison
Compare FSFG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- MDWD
- Stock Information
- Founded
- FSFG 2008
- MDWD 2000
- Country
- FSFG United States
- MDWD Israel
- Employees
- FSFG N/A
- MDWD N/A
- Industry
- FSFG Savings Institutions
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- FSFG Finance
- MDWD Health Care
- Exchange
- FSFG Nasdaq
- MDWD Nasdaq
- Market Cap
- FSFG N/A
- MDWD 184.8M
- IPO Year
- FSFG 2008
- MDWD 2014
- Fundamental
- Price
- FSFG $25.18
- MDWD $17.64
- Analyst Decision
- FSFG Buy
- MDWD Strong Buy
- Analyst Count
- FSFG 1
- MDWD 1
- Target Price
- FSFG $31.00
- MDWD $25.00
- AVG Volume (30 Days)
- FSFG 13.9K
- MDWD 68.1K
- Earning Date
- FSFG 01-28-2025
- MDWD 11-26-2024
- Dividend Yield
- FSFG 2.38%
- MDWD N/A
- EPS Growth
- FSFG 66.39
- MDWD N/A
- EPS
- FSFG 1.98
- MDWD N/A
- Revenue
- FSFG $68,091,000.00
- MDWD $19,720,000.00
- Revenue This Year
- FSFG N/A
- MDWD $10.37
- Revenue Next Year
- FSFG $2.77
- MDWD $26.36
- P/E Ratio
- FSFG $12.72
- MDWD N/A
- Revenue Growth
- FSFG N/A
- MDWD N/A
- 52 Week Low
- FSFG $14.55
- MDWD $11.04
- 52 Week High
- FSFG $30.94
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- FSFG 41.19
- MDWD 49.76
- Support Level
- FSFG $24.20
- MDWD $15.80
- Resistance Level
- FSFG $27.17
- MDWD $19.60
- Average True Range (ATR)
- FSFG 0.79
- MDWD 0.98
- MACD
- FSFG -0.02
- MDWD 0.06
- Stochastic Oscillator
- FSFG 33.00
- MDWD 48.42
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.